Investigation of the effect of SGLT-2 inhibitors on the triglyceride/glucose index in diabetic patients: a cross-sectional study
Abstract
Objectives: The aim of this study is to estimate the change in the Triglyceride Glucose Index (TyG index), in patients with type 2 Diabetes Mellitus who are using a sodium-glucose cotransporter-2 (SGLT2) inhibitor, and to evaluate the effect of these drugs on triglyceride glucose index.
Methods: This is a cross-sectional study of 55 diabetic patients in our internal medicine clinic in Turkey. Triglyceride, glucose, and glycosylated hemoglobin (HbA1c) values were measured at the beginning of the treatment and the 3rd-month follow-up. The TyG index of the patients before starting SGLT-2 inhibitor treatment and at the end of 3 months of treatment was calculated by the researchers using the data in the hospital digital records.
Results: The mean age of 55 patients (56.4% male) was 62.7±10.2 years. The number of patients using dapagliflozin 10 mg was 15 (27.3%) and the number of patients using empagliflozin was 41 (72.8%). It was determined that fasting plasma glucose, TyG index, and HbA1c values before starting SGLT-2 inhibitor treatment and in the 3rd month of treatment decreased significantly (P<0.001, P=0.002 and P<0.001, respectively). According to the correlation analysis results between TyG index and HbA1c, it was determined that the values both before treatment and in the 3rd month of treatment showed a correlation (r=0.516, P<0.001 and r=0.448, P=0.001, respectively).
Conclusions: SGLT-2 inhibitor usage significantly reduces TyG index in diabetic patients, and new…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 55 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.